| Literature DB >> 27776266 |
Paulina R Davis1, Ginevra Giannini2, Karin Rudolph2, Nathaniel Calloway3, Christopher M Royer2, Tina L Beckett3, M Paul Murphy4, Frederick Bresch5, Dieter Pagani6, Thomas Platt4, Xiaohong Wang3, Amy Skinner Donovan3, Tiffany L Sudduth7, Wenjie Lou3, Erin Abner3, Richard Kryscio3, Donna M Wilcock8, Edward G Barrett2, Elizabeth Head9.
Abstract
Beta-amyloid (Aβ) immunotherapy is a promising intervention to slow Alzheimer's disease. Aging dogs naturally accumulate Aβ and show cognitive decline. An active vaccine against fibrillar Aβ 1-42 (VAC) in aged beagles resulted in maintenance but not improvement of cognition along with reduced brain Aβ. Behavioral enrichment (ENR) led to cognitive benefits but no reduction in Aβ. We hypothesized cognitive outcomes could be improved by combining VAC with ENR in aged dogs. Aged dogs (11-12 years) were placed into 4 groups: (1) control/control (C/C); (2) control/VAC (C/V); (3) ENR/control (E/C); and (4) ENR/VAC (E/V) and treated for 20 months. VAC decreased brain Aβ, pyroglutamate Aβ, increased cerebrospinal fluid Aβ 42 and brain-derived neurotrophic factor RNA levels but also increased microhemorrhages. ENR reduced brain Aβ and prevented microhemorrhages. The combination treatment resulted in a significant maintenance of learning over time, reduced Aβ, and increased brain-derived neurotrophic factor mRNA despite increased microhemorrhages; however, there were no benefits to memory. These results suggest that the combination of immunotherapy with behavioral enrichment leads to cognitive maintenance associated with reduced neuropathology that may benefit people with Alzheimer's disease.Entities:
Keywords: Aging; Alzheimer's disease; Brain; Brain-derived neurotrophic factor; Canine; Cerebrovascular; Dog; Immunotherapy
Mesh:
Substances:
Year: 2016 PMID: 27776266 PMCID: PMC5154836 DOI: 10.1016/j.neurobiolaging.2016.09.007
Source DB: PubMed Journal: Neurobiol Aging ISSN: 0197-4580 Impact factor: 4.673